loadpatents
name:-0.016443014144897
name:-0.012634038925171
name:-0.0063149929046631
Geletneky; Karsten Patent Filings

Geletneky; Karsten

Patent Applications and Registrations

Patent applications and USPTO patent grants for Geletneky; Karsten.The latest application filed is for "cancer therapy with a parvovirus combined with bevacizumab".

Company Profile
5.16.16
  • Geletneky; Karsten - Heidelberg DE
  • Geletneky, Karsten - Heidelbers DE
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Parvovirus formulation for treating tumors
Grant 11,324,788 - Leuchs , et al. May 10, 2
2022-05-10
Cancer Therapy With A Parvovirus Combined With Bevacizumab
App 20210060102 - Geletneky; Karsten ;   et al.
2021-03-04
Cancer therapy with a parvovirus combined with bevacizumab
Grant 10,813,959 - Geletneky , et al. October 27, 2
2020-10-27
Parvovirus Formulation For Treating Tumors
App 20200215134 - Leuchs; Barbara ;   et al.
2020-07-09
Parvovirus formulation for treating tumors
Grant 10,624,935 - Leuchs , et al.
2020-04-21
Use of parvovirus for eliminating cancer stem cells (CSCs)
Grant 10,525,091 - Rommelaere , et al. J
2020-01-07
Cancer therapy with a parvovirus combined with a BCL-2 inhibitor
Grant 10,406,185 - Marchini , et al. Sept
2019-09-10
Cancer Therapy With A Parvovirus Combined With A Bcl-2 Inhibitor
App 20180117104 - MARCHINI; Antonio ;   et al.
2018-05-03
Parvovirus Formulation For Treating Tumors
App 20180110813 - Leuchs; Barbara ;   et al.
2018-04-26
Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
Grant 9,889,169 - Marchini , et al. February 13, 2
2018-02-13
Cancer Therapy With A Parvovirus Combined With Bevacizumab
App 20180028583 - Geletneky; Karsten ;   et al.
2018-02-01
Oncolytic virotherapy for prevention of tumor recurrence
Grant 9,861,669 - Rommelaere , et al. January 9, 2
2018-01-09
USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
App 20170266244 - Rommelaere; Jean ;   et al.
2017-09-21
Use of parvovirus for eliminating cancer stem cells (CSCs)
Grant 9,700,588 - Rommelaere , et al. July 11, 2
2017-07-11
Method for Cancer Therapy Based on Co-Administration of a Parvovirus and a Cytokine
App 20160367609 - KIPRIJANOVA; Irina ;   et al.
2016-12-22
Method for brain cancer therapy by co-administration of a parvovirus and interferon-gamma
Grant 9,446,099 - Kiprijanova , et al. September 20, 2
2016-09-20
Cancer Therapy With A Parvovirus Combined With A Bcl-2 Inhibitor
App 20160082056 - MARCHINI; Antonio ;   et al.
2016-03-24
Parvovirus Cancer Therapy and Combination with Chemotherapy
App 20140234261 - ROMMELAERE; Jean ;   et al.
2014-08-21
USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
App 20130209413 - Rommelaere; Jean ;   et al.
2013-08-15
Parvovirus cancer therapy and combination with chemotherapy
Grant 8,414,883 - Rommelaere , et al. April 9, 2
2013-04-09
Oncolytic Virotherapy for Prevention of Tumor Recurrence
App 20120237483 - Rommelaere; Jean ;   et al.
2012-09-20
Method for Cancer Therapy Based on a Co-Administration of a Parvovirus and a Cytokine
App 20120213734 - Kiprijanova; Irina ;   et al.
2012-08-23
Parvovirus Cancer Therapy and Combination with Chemotherapy
App 20110020287 - Rommelaere; Jean ;   et al.
2011-01-27
Use of parvovirus for brain tumor therapy
Grant 7,179,456 - Rommelaere , et al. February 20, 2
2007-02-20
Adeno-associated virus-its diagnostic use with early abortion
Grant 6,927,281 - Kern , et al. August 9, 2
2005-08-09
Use of parvovirus for brain tumor therapy
App 20040220124 - Rommelaere, Jean ;   et al.
2004-11-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed